NFκB Inhibitor manufacturers
- NFκB Inhibitor
-
- $7.00
-
2020-02-14
- CAS:213546-53-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100kg
|
| | NFκB Inhibitor Basic information |
| Product Name: | NFκB Inhibitor | | Synonyms: | FGF-4 PRECURSOR (7-22) (HUMAN)-EBP-1 (359-368) (HUMAN);FIBROBLAST GROWTH FACTOR-4 PRECURSOR (7-22) (HUMAN)-NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT (359-368) (HUMAN);H-ALA-ALA-VAL-ALA-LEU-LEU-PRO-ALA-VAL-LEU-LEU-ALA-LEU-LEU-ALA-PRO-VAL-GLN-ARG-LYS-ARG-GLN-LYS-LEU-MET-PRO-OH;HST-1 PRECURSOR (7-22) (HUMAN)-DNA-BINDING FACTOR KBF1 (359-368) (HUMAN);AAVALLPAVLLALLAPVQRKRQKLMP;NF-KAPPA-B SN50;NF-KAPPA-B SN50, CELL-PERMEABLE INHIBITOR PEPTIDE;NF-KAPPAB SN50, CELL-PERMEABLE INHIBITORY PEPTIDE | | CAS: | 213546-53-3 | | MF: | C129H230N36O29S | | MW: | 2781.5 | | EINECS: | | | Product Categories: | | | Mol File: | 213546-53-3.mol |  |
| | NFκB Inhibitor Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | form | film | | color | colorless | | Water Solubility | Water : ≥ 50 mg/mL (17.98 mM) | | Sequence | Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro | | InChIKey | FAWLNURBQMTKEB-URDPEVQOSA-N |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | NFκB Inhibitor Usage And Synthesis |
| Uses | NFkappaB Inhibitor is inhibits translocation of the NFκB active complex into the nucleus. | | Biochem/physiol Actions | SN50 is an NF-κB cell permeable inhibitory peptide. The SN50 sequence contains the nuclear localization sequence (NLS residues 360-369) of the transcription factor NFκB p50 linked to a peptide cell-permeabilization sequence, the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). SN50 Peptide inhibits translocation of the NF-κB active complex into the nucleus. | | in vivo | Treatment with SN50 accelerates the recovery of motor functional outcome from 1st to 4th day. Animals subjected to SN50 pretreatment demonstrate a significant decrease in the visuospatial learning latencies relative to the control group at 7 and 8 days post-TBI. Pretreatment with SN50 results in a significant reduction of NF-κB p65 protein levels from 6 to 48 h post-TBI and TNF-a protein levels from 12 to 48 h post-TBI[1]. | | IC 50 | NF-κB |
| | NFκB Inhibitor Preparation Products And Raw materials |
|